WM

FMCSA Administrator Hutcheson to Keynote Women In Trucking Accelerate! Conference

Retrieved on: 
Tuesday, September 27, 2022
YouTube, Federal Motor Carrier Safety Administration, Walmart, Daimler Trucks North America, Employment, Safety, Woman, Acceleration, Twitter, Robin, WM, WIT, Association, LinkedIn, Hilton Anatole, PACCAR, Ryder, Industry, CEO, XPO Logistics, Women In Trucking Association, Inc, Instagram, Transport, Leadership, Yellow, FMCSA, UPS, TikTok, Conference, Marketing, Peterbilt, Man, FedEx, Video game, Bridgestone, Navistar International, Facebook, Great Dane, Amazon

PLOVER, Wis., Sept. 27, 2022 /PRNewswire-PRWeb/ -- The Women In Trucking Association (WIT) announces that Robin Hutcheson, the newly confirmed administrator of the Federal Motor Carrier Safety Administration (FMCSA), will be the opening keynote Nov. 14 at its upcoming Accelerate! Conference & Expo. The conference, which will take place Nov. 13-16 at the Hilton Anatole in Dallas, TX, is the largest event to encourage employment, address obstacles, and celebrate the successes of women in the trucking industry. WIT expects more than 1,300 attendees this year.

Key Points: 
  • The Women In Trucking Association (WIT) announces that Robin Hutcheson, the newly confirmed administrator of the Federal Motor Carrier Safety Administration (FMCSA), will be the opening keynote Nov. 14 at its upcoming Accelerate!
  • PLOVER, Wis., Sept. 27, 2022 /PRNewswire-PRWeb/ -- The Women In Trucking Association (WIT) announces that Robin Hutcheson, the newly confirmed administrator of the Federal Motor Carrier Safety Administration (FMCSA), will be the opening keynote Nov. 14 at its upcoming Accelerate!
  • The conference, which will take place Nov. 13-16 at the Hilton Anatole in Dallas, TX, is the largest event to encourage employment, address obstacles, and celebrate the successes of women in the trucking industry.
  • About Women In Trucking Association, Inc.
    Women In Trucking Association, Inc. is a nonprofit association established to encourage the employment of women in the trucking industry, promote their accomplishments and minimize obstacles faced by women working in the trucking industry.

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

Retrieved on: 
Tuesday, September 27, 2022
Lists of diseases, Neutropenia, Therapy, WHIM syndrome, Safety, Infection, ET, Trial of the century, Q&A, ANC, Risk, Neutrophil, WM, Immunodeficiency, Blood, Population, Private Securities Litigation Reform Act, Partnership, Forward-looking statement, U.S. Securities and Exchange Commission, Patient, Degenerative disease, Clinical trial, Cancer, B-cell lymphoma, Biology, Quality of life, CN, Bone marrow, Cell, Medication, Birth, G-CSF, Research, Security (finance), GLOBE, SEC, CXCR4, WHIM, Immune system, Severe congenital neutropenia, Cyclic neutropenia, Dentistry, Pharmaceutical industry

In addition, we are encouraged by the results of three exploratory sub-analyses we completed assessing the potential of mavorixafor to treat chronic neutropenia as monotherapy or concurrently with G-CSF.

Key Points: 
  • In addition, we are encouraged by the results of three exploratory sub-analyses we completed assessing the potential of mavorixafor to treat chronic neutropenia as monotherapy or concurrently with G-CSF.
  • We believe these data support the further study of mavorixafors potential to enable patients to reduce or even discontinue G-CSF treatment.
  • We anticipate this amended trial to begin generating additional clinical data in the first half of 2023.
  • X4 will host an investor webinar to present and discuss the new data today from 8:00 - 9:15 am ET.

Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors

Retrieved on: 
Thursday, September 22, 2022
Odds, Central nervous system, Neuroblastoma, Safety, Radiation, Osteosarcoma, COVID-19, Twitter, Risk, FDA, HGG, Food, WM, Multiple myeloma, Lymphoma, Sarcoma, Neoplasm, Part, LinkedIn, Population, MM, European Commission, News, U.S. Securities and Exchange Commission, Survival, Patient, Exchange, Cancer, NCI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, B-cell lymphoma, CEO, Rhabdomyosarcoma, Christian democracy, Regulation, Progression-free survival, Brain, Diffuse intrinsic pontine glioma, Pediatric ependymoma, PDC, NASDAQ, Collection, Astrocytoma, Research, Security (finance), GLOBE, Glioblastoma, Marketing, Drug discovery, DLBCL, National Institute, Pharmaceutical industry, Facebook

The funding allows for an expansion from the Part 1a into the Part 1b portion of the companys ongoing Phase 1 pediatric study.

Key Points: 
  • The funding allows for an expansion from the Part 1a into the Part 1b portion of the companys ongoing Phase 1 pediatric study.
  • The currently ongoing Phase 1a is designed to determine the safety, tolerability, and initial efficacy of iopofosine in pediatric brain tumors whereas the Phase 1b is designed to identify the dose and dosing regimen that results in optimal efficacy.
  • Unfortunately, patients with HGGs often have very poor prognoses, with limited treatment options, said James Caruso, president and CEO of Cellectar.
  • The company is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase 2 CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase 1 CLOVER-2 study.

NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment

Retrieved on: 
Tuesday, September 20, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Lymph, BTK, Safety, Blood, Lancet, National Institute for Health and Care Excellence, Patient, Jazz Pharmaceuticals, Lymphoid leukemia, Technology, FAD, National Health Service, NASDAQ, Research, Disease, National Institute, QALY, COVID-19, Food, Company, Intellectual property, B-cell lymphoma, Bone marrow, PARP, SSE, Man, Spleen, Food and Drug Administration, Woman, FDA, Review, Global health, Goal, Tislelizumab, Novartis, Tissue, NICE, Marketing, Half-life, Therapy, Twitter, WM, Form 10-Q, Rituximab, Cancer, Quality of life, Standard of care, Private Securities Litigation Reform Act, Pharmacokinetics, BLA, Bristol Myers Squibb, Union, Pharmaceutical industry, Hospital, BeiGene

This decision from NICE marks BRUKINSA as the first and only treatment for WM to be recommended for routine use in England and Wales.

Key Points: 
  • This decision from NICE marks BRUKINSA as the first and only treatment for WM to be recommended for routine use in England and Wales.
  • NICEs positive recommendation for zanubrutinib allows eligible patients in England and Wales to access an important new treatment option that may offer improved outcomes compared to the current standard of care.
  • Our expansive portfolio is directed predominantly by our internal colleagues supporting clinical trials in more than 45 countries and regions.
  • Treatment and outcome patterns in European patients with Waldenstrms macroglobulinaemia: a large, observational, retrospective chart review.

WM Datenservice Establishes Another Important Element for the Digitalization of the Securities Sector with Nucleus Finance as its First partner

Retrieved on: 
Wednesday, September 14, 2022
Technology, Finance, Fintech, Professional Services, Digital Cash Management, Digital Assets, Blockchain, Internet, Cryptocurrency, IOT (Internet of Things), Web3, Dropbox, Mobility as a service, ACTUS, AWS, WM, SFC, Microsoft, Adobe, Ownership, Technology, Risk management, Solution, Architecture, Ariadne, Fintech Valley Vizag, Cryptocurrency, Warehouse, Google, Blockchain

As part of the service, data of issued securities is recorded, structured and forwarded to tokenizers and crypto securities registries.

Key Points: 
  • As part of the service, data of issued securities is recorded, structured and forwarded to tokenizers and crypto securities registries.
  • Together, Nucleus Finance AG and WM Datenservice have further developed this new service for "Tokenization as a Service" (TaaS) as part of a joint project.
  • An initial proof of concept project for a classic bond and a structured product was successfully implemented based on data from WM Datenservice and systems from Nucleus Finance AG.
  • For the time being, Nucleus Finance AG and WM Datenservice will focus their TaaS services on simple structured products such as certificates, warrants and bonds.

WM to Acquire Controlling Interest in Avangard Innovative's U.S. Business

Retrieved on: 
Tuesday, September 13, 2022
NYSE, Recycling, WM, Knowledge, Renewable energy, Avangard, Waste management, Growth, Industry, Environment, Investment, Automation, CEO, Goal, Solution, Annual report, Vinson & Elkins, Plastic, Food, Collection, PCR, Natural gas, Plant, Failure, Warehouse, Natura & Co, Dow

HOUSTON, Sept. 13, 2022 /PRNewswire/ -- WM (NYSE:WM) today announced that it has agreed to acquire a controlling interest in Avangard Innovative's U.S. business, which will operate as Natura PCR – an independent company expected to scale and grow recycling capacity to produce an estimated 400 million pounds per year of post-consumer resin (PCR) in five years. Through Natura PCR, WM expects to deliver new recycling capabilities for its customers and provide circular solutions for films and clear plastic wrap used commercially, such as plastic stretch wrap for pallets, furniture film, grocery bags and potentially shrink wrap around food and beverage containers.

Key Points: 
  • "WM's controlling interest in Natura PCR positions us to grow and scale rapidly in the emerging PCR space," said Jim Fish, president and CEO, WM.
  • Dow has also been working with Avangard Innovative since early 2020, purchasing the company's PCR pellets to produce REVOLOOP, Dow's product line with PCR content.
  • With 30 years of experience, Avangard Innovative offers full-service waste management and recycling optimization solutions at all levels of the process.
  • WM assumes no obligation to update any forward-looking statement, whether as a result of future events, circumstances or developments or otherwise.

WM to Acquire Controlling Interest in Avangard Innovative's U.S. Business

Retrieved on: 
Tuesday, September 13, 2022
NYSE, Recycling, WM, Knowledge, Renewable energy, Avangard, Waste management, Growth, Industry, Environment, Investment, Automation, CEO, Goal, Solution, Annual report, Vinson & Elkins, Plastic, Food, Collection, Multimedia, PCR, Natural gas, Plant, Failure, Warehouse, Natura & Co, Dow

HOUSTON, Sept. 13, 2022 /PRNewswire/ -- WM (NYSE:WM) today announced that it has agreed to acquire a controlling interest in Avangard Innovative's U.S. business, which will operate as Natura PCR – an independent company expected to scale and grow recycling capacity to produce an estimated 400 million pounds per year of post-consumer resin (PCR) in five years. Through Natura PCR, WM expects to deliver new recycling capabilities for its customers and provide circular solutions for films and clear plastic wrap used commercially, such as plastic stretch wrap for pallets, furniture film, grocery bags and potentially shrink wrap around food and beverage containers.

Key Points: 
  • "WM's controlling interest in Natura PCR positions us to grow and scale rapidly in the emerging PCR space," said Jim Fish, president and CEO, WM.
  • Leading materials science company, Dow , has been working with WM to help increase the recycling rate of plastics and create sustainable solutions in packaging, infrastructure and consumer applications.
  • Dow has also been working with Avangard Innovative since early 2020, purchasing the company's PCR pellets to produce REVOLOOP, Dow's product line with PCR content.
  • WM assumes no obligation to update any forward-looking statement, whether as a result of future events, circumstances or developments or otherwise.

Global Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 8, 2022
Health, General Health, Clinical trial, Macroglobulinemia, Therapy, Patient, Pharmaceutical industry, WM

This reports provides a data-driven overview of the current and future competitive landscape in Waldenstrom Macroglobulinemia therapeutics.

Key Points: 
  • This reports provides a data-driven overview of the current and future competitive landscape in Waldenstrom Macroglobulinemia therapeutics.
  • In 2022, there will be more than 14,000 incident cases of WM across 16 pharmaceutical markets.
  • There are three leading marketed drugs for the treatment of WM, and Beigene is a key player in the disease space.
  • Commercial sponsors dominate clinical trial development in WM, with the US emerging as the key countries for conducting trials in WM.

X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia

Retrieved on: 
Wednesday, August 31, 2022
G-CSF, B-cell lymphoma, Partnership, Security (finance), Safety, Cancer, CXCR4, Trial of the century, Lists of diseases, Research, Neutropenia, Medication, Immunodeficiency, WHIM, WHIM syndrome, SEC, U.S. Securities and Exchange Commission, Cyclic neutropenia, GLOBE, WM, Biology, Immune system, Therapy, Risk, Clinical trial, Private Securities Litigation Reform Act, Q&A, Forward-looking statement, Patient, Pharmaceutical industry, Infection, Hypogammaglobulinemia, Myelokathexis

Members of X4 Pharmaceuticals management team will present clinical data on 25 patients from this fully enrolled trial and discuss mavorixafors potential to treat broader chronic neutropenia populations beyond its lead indication in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome.

Key Points: 
  • Members of X4 Pharmaceuticals management team will present clinical data on 25 patients from this fully enrolled trial and discuss mavorixafors potential to treat broader chronic neutropenia populations beyond its lead indication in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome.
  • The clinical trial ( NCT04154488 ) is a proof-of-concept Phase 1b open-label, multicenter study designed to assess the safety and tolerability of daily, oral mavorixafor with or without G-CSF, in participants with chronic neutropenic disorders including severe congenital, idiopathic, or cyclic neutropenia.
  • Participants were dosed with a single dose of oral mavorixafor to assess the magnitude of treatment response.
  • X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with diseases of the immune system.

Align Capital Partners Realizes Investment in WilliamsMarston

Retrieved on: 
Tuesday, August 30, 2022
Consulting, Accounting, Professional Services, Finance, Kelso & Company, ACP, Partnership, Technology, APriori Capital Partners, LLP, Kelso, San Francisco Bay Area, Sale, IPO, Kirkland & Ellis, CFO, Company, WM, Entrepreneurship, Leadership, Growth, Industry, Financial services, Security (finance)

Align Capital Partners (ACP) is pleased to announce the sale of its interest in WilliamsMarston LLC ("WilliamsMarston," the "Firm" or WM) to Kelso & Company (Kelso).

Key Points: 
  • Align Capital Partners (ACP) is pleased to announce the sale of its interest in WilliamsMarston LLC ("WilliamsMarston," the "Firm" or WM) to Kelso & Company (Kelso).
  • Headquartered in Boston, MA, WilliamsMarston is a differentiated, national leader in providing complex accounting, tax and valuation advisory services.
  • Align Capital Partners is a growth-oriented private equity firm that partners with business owners and management teams to create shared success.
  • ACP manages $775 million in committed capital with investment teams in Cleveland and Dallas.